Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions - PubMed
7 hours ago
- #secondary prevention
- #ischemic stroke
- #antithrombotic therapy
- Antithrombotic therapy is crucial for reducing stroke recurrence in noncardioembolic ischemic stroke.
- Antiplatelet monotherapy is effective for secondary stroke prevention in noncardioembolic stroke cases.
- Dual-antiplatelet therapy is superior to monotherapy in the acute period after minor stroke or transient ischemic attack.
- Long-term combination antiplatelet medications or full-dose anticoagulation show limited reduction in ischemic events but increase bleeding risk.
- Emerging factor XI/XIa inhibitors may enhance stroke prevention without increasing bleeding risks.
- The OCEANIC-STROKE trial demonstrated the efficacy of dual-pathway inhibition with factor XIa inhibitor asundexian combined with antiplatelet therapy.
- This review discusses current evidence and ongoing trials of novel factor XI/XIa inhibitors for stroke prevention.